Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?
Optimales Management des klinischen T2N0-Magenadenokarzinoms: Operation oder zuerst Chemotherapie?
Journal of Surgical Oncology · 2026-11 · 134 (6) · 850-857
DOI: 10.1002/jso.70354 ↗Auf einen Blick
Bei 3.676 Patient:innen mit cT2N0-Magenadenokarzinom war Chemotherapie zusätzlich zur Operation mit besserem Überleben verbunden. Adjuvante Chemotherapie schnitt besser ab als perioperative Chemotherapie.
Fragestellung
Welche Rolle und Reihenfolge der Chemotherapie ist bei reseziertem cT2N0-Magenadenokarzinom mit Blick auf das Gesamtüberleben mit besseren Ergebnissen verbunden?
Methode
Auswertung der National Cancer Database 2004 bis 2020; Patient:innen mit cT2N0-Magenadenokarzinom nach chirurgischer Resektion; Vergleich von keiner, perioperativer und adjuvanter Chemotherapie.
Ergebnisse
Von 3.676 Patient:innen erhielten 61,3 % keine Chemotherapie, 19,4 % perioperative und 19,2 % adjuvante Chemotherapie. Beide Chemotherapiestrategien waren mit geringerer Mortalität als keine Chemotherapie verbunden; AT war gegenüber PC günstiger (HR 0,79; p = 0,015).
Schlussfolgerung der Autor:innen
Patient:innen mit cT2N0-Magenadenokarzinom profitieren laut Autor:innen von Chemotherapie zusätzlich zur Operation. Sie sehen adjuvante Chemotherapie nach upfront Resektion als günstiger als perioperative Chemotherapie.
Kernaussagen
- Chemotherapie plus Operation war mit besserem Überleben verbunden.
- Adjuvante Chemotherapie schnitt besser ab als perioperative Chemotherapie.
- 28,8 % waren in der finalen Pathologie höher gestuft.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 16.08.2026. Verfasst von Elizabeth J Olecki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Gastrectomy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Randomized controlled trials have demonstrated substantial benefit of perioperative chemotherapy (PC) and surgery for locally advanced gastric adenocarcinoma. Patients with clinical T2N0 (cT2N0) gastric adenocarcinoma were included in these trials, but the benefit of PC remains unclear in this intermediate‐stage disease due to the small number of patients included. The goal of this study was to determine the role and sequencing of chemotherapy for resected cT2N0 gastric adenocarcinoma.
Methods
The National Cancer Database from 2004 to 2020 was used to identify patients with cT2N0 gastric adenocarcinoma who underwent surgical resection. Patients were stratified by receipt of chemotherapy into three groups: (1) no chemotherapy, (2) perioperative chemotherapy (PC), and (3) adjuvant chemotherapy (AT). The primary outcome was overall survival.
Results
Of 3676 patients with cT2N0 gastric adenocarcinoma, 61.3% received no chemotherapy, 19.4% received PC, and 19.2% received AT. Of the 2961 patients who underwent upfront surgical resection, 28.8% (854) were upstaged on final pathology. Multivariable survival analysis revealed that both PC and AT were associated with a decreased mortality compared to no chemotherapy (0.64 and 0.68, respectively, p < 0.001). AT was associated with a 21% decrease in mortality compared to PC (HR 0.79, p = 0.015).
Conclusion
Patients presenting with cT2N0 gastric adenocarcinoma benefit from chemotherapy in addition to surgery, although a minority of patients received guideline concordant care. Patients who received adjuvant chemotherapy had superior outcomes compared to those who received perioperative chemotherapy. The optimal treatment for cT2N0 gastric cancer should include surgery and chemotherapy, and consideration should be given to a strategy of upfront surgical resection and adjuvant therapy rather than perioperative chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, Pennsylvania, USA.
- Rush University Medical College, Section of Hepatopancreatobilary Surgery, Division of Surgical Oncology, Chicago, Illinois, USA.
- Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, California, USA.
ORCID-Profile: Elizabeth J Olecki, Matthew E B Dixon, June S Peng
Zitieren
APA
Olecki, E. J., Holguin, R. P., Dixon, M. E. B., & Peng, J. S. (2026). Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?. Journal of Surgical Oncology, 134(6), 850-857. https://doi.org/10.1002/jso.70354
Vancouver
Olecki EJ, Holguin RP, Dixon MEB, Peng JS. Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?. Journal of Surgical Oncology. 2026;134(6):850-857. doi:10.1002/jso.70354
BibTeX
@article{Olecki2026,
author = {Olecki, Elizabeth J and Holguin, Rolfy Perez and Dixon, Matthew E B and Peng, June S},
title = {Optimal Management of Clinical T2N0 Gastric Adenocarcinoma: Surgery or Chemotherapy First?},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {134},
number = {6},
pages = {850--857},
doi = {10.1002/jso.70354}
}
EUVIMED